Epidemiology
- Indications: multiple myeloma, mantle cell lymphoma
- In refractory or advancing multiple myeloma, complete clinical responses have been achieved
Pharmacology
- Proteasome Inhibitor
Adverse Effects
- Acute Lung Injury-ARDS (see Acute Lung Injury-ARDS)
References
- xxx